NASDAQ : IMVT
Immunovant, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 29.64 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.12B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.95B |
| Enterprise Value | 5.15B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 206.55M |
| Shares Outstanding | 206.55M |
| Shares Change (YoY) | +21.12% |
| Shares Change (QoQ) | +0.90% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 54.75% |
| Float | 91.77M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.18 |
| P/TBV Ratio | 8.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.27 |
| Quick Ratio | 6.82 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -80.10% |
| Return on Assets (ROA) | -46.73% |
| Return on Invested Capital (ROIC) | -52.64% |
| Return on Capital Employed (ROCE) | -76.97% |
| Weighted Average Cost of Capital (WACC) | 8.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 315 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -698,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +34.73% |
| 50-Day Moving Average | 34.56 |
| 200-Day Moving Average | 32.04 |
| Relative Strength Index (RSI) | 39.63 |
| Average Volume (20 Days) | 1,385,560 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18.27M |
| Short Previous Month | 17.42M |
| Short % of Shares Out | 8.85% |
| Short % of Float | 19.91% |
| Short Ratio (days to cover) | 10.91 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -566.00M |
| Pretax Income | -538.92M |
| Net Income | -538.22M |
| EBITDA | -565.61M |
| EBIT | -566.00M |
| Earnings Per Share (EPS) | -$2.82 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 797.80M |
| Total Debt | n/a |
| Net Cash | 797.80M |
| Net Cash Per Share | $3.86 |
| Equity (Book Value) | 735.39M |
| Book Value Per Share | 3.57 |
| Working Capital | 734.08M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -414.30M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 394,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -414.31M |
| FCF Per Share | -$2.01 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.12% |
| Shareholder Yield | -21.12% |
| Earnings Yield | -9.78% |
| FCF Yield | -6.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $48.88 |
| Price Target Difference | 69.78% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |